Skip to main content
رجوع
PHAR logo

Pharming Group N.V.

جودة البيانات: 100%
PHAR
NASDAQ Healthcare Biotechnology
KWD 16.01
▲ KWD 0.65 (4.23%)
القيمة السوقية: 1.06B
مُدرج أيضًا باسم PHGUF OTC
نطاق اليوم
KWD 15.40 KWD 16.13
نطاق 52 أسبوعًا
KWD 7.50 KWD 21.34
حجم التداول
43,315
متوسط 50 يوم / 200 يوم
KWD 17.05 / KWD 14.62
الإغلاق السابق
KWD 15.36

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 436.3 0.4
P/B 4.5 2.9
ROE % 1.1 3.8
Net Margin % 0.8 3.9
Rev Growth 5Y % 12.7 10.0
D/E 0.5 0.2

السعر المستهدف للمحللين

Hold
KWD 39.500 +146.7%
Low: KWD 37.000 High: KWD 42.000
مكرر الربحية المستقبلي
95.0
ربحية السهم المستقبلية
KWD 0.169
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
410 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 0.250
KWD 0.229 – KWD 0.274
600 M 1
FY2029 KWD 0.485
KWD 0.444 – KWD 0.532
440 M 1
FY2028 KWD 0.180
KWD 0.165 – KWD 0.197
350 M 1

النقاط الرئيسية

Revenue grew 12.73% annually over 5 years — strong growth
ROE of 1.07% is below average
Debt/Equity of 0.49 — conservative balance sheet
Generating 41.98M in free cash flow
P/E of 436.32 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4.68%

النمو

Revenue Growth (5Y)
12.73%
Revenue (1Y)8.05%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
1.07%
ROIC3.52%
Net Margin0.76%
Op. Margin5.13%

الأمان

Debt / Equity
0.49
Current Ratio2.20
Interest Coverage0.91

التقييم

P/E Ratio
436.32
P/B Ratio4.50
EV/EBITDA63.89
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8.05% Revenue Growth (3Y) 14.41%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 12.73% Earnings Growth (5Y) -37.54%
Profitability
Revenue (TTM) 321.12M Net Income (TTM) 2.43M
ROE 1.07% ROA 0.57%
Gross Margin 87.90% Operating Margin 5.13%
Net Margin 0.76% Free Cash Flow (TTM) 41.98M
ROIC 3.52% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.49 Current Ratio 2.20
Interest Coverage 0.91 Dividend Yield 0.00%
Valuation
P/E Ratio 436.32 P/B Ratio 4.50
P/S Ratio 3.31 PEG Ratio -3.67
EV/EBITDA 63.89 Dividend Yield 0.00%
Market Cap 1.06B Enterprise Value 1.05B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 321.12M 297.20M 245.32M 205.62M 198.87M
Net Income 2.43M -11.84M -10.55M 13.67M 16.00M
EPS (Diluted) 0.03 -0.17 -0.14 0.16 0.18
Gross Profit 282.27M 261.80M 220.10M 188.06M 177.73M
Operating Income 16.49M -8.62M -5.39M 18.23M 13.56M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 425.52M 399.99M 462.85M 425.80M 397.32M
Total Liabilities 189.68M 178.92M 244.07M 221.16M 204.40M
Shareholders' Equity 235.84M 221.06M 218.78M 204.64M 192.92M
Total Debt 115.78M 112.31M 171.55M 166.69M 161.76M
Cash & Equivalents 124.32M 54.94M 61.74M 207.34M 191.92M
Current Assets 254.88M 278.44M 316.34M 277.50M 249.44M
Current Liabilities 115.79M 73.80M 77.97M 59.70M 46.77M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#692 of 1024
36

النشاط الأخير

دخل Cash Flow Compounder
Mar 24, 2026